Authors
Loading...
Retrospective study shows that neoadjuvant immunochemotherapy enhances pathological response and survival in LA-ESCC, suggesting it may be preferable to chemotherapy.
Ge et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: